ArticleBMJ open2021
Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study.
Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Polypharmacy, Potential Drug-Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study.Neurology and therapy · 2026Article
- Personality Traits and Their Association With Medication Non-Adherence in Patients With Multiple Sclerosis.CNS neuroscience & therapeutics · 2026Article
- Antiretroviral utilization and adherence before vs. after expansion of a provincial drug insurance policy.AIDS (London, England) · 2026Article
- Psychiatric Comorbidity Does Not Enhance Prescription Opioid Use in Inflammatory Bowel Disease as It Does in the General Population.Inflammatory bowel diseases · 2025Article
- Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis.Neurology and therapy · 2024Review
- Personalized Intervention to Improve Medication Adherence for Persons with Multiple Sclerosis.Patient preference and adherence · 2024Article
- Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Adherence to Therapy in Patients with Multiple Sclerosis-Review.International journal of environmental research and public health · 2022Review
- Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.Frontiers in neurology · 2022Article
- No consensus about consensus?Neurological research and practice · 2021Article
- Characterizing the diversity of the multiple sclerosis population in Canada: A scoping review.Multiple sclerosis journal - experimental, translational and clinicalReview
- Using an Intervention Mapping Approach to Improve Adherence to Disease-Modifying Treatment in Multiple Sclerosis.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveTo determine whether better medication adherence in multiple sclerosis (MS) might be due to specialised disease-modifying drug (DMD) support programmes by: (1) establishing higher adherence in MS than in other chronic diseases and (2) determining if higher adherence is associated with patient-specific or treatment-specific factors.
designRetrospective cohort study with data from 1 January 1996 to 31 December 2015.
settingPopulation-based health administrative data from three Canadian provinces.
participantsIndividual cohorts were created using validated case definitions for MS, epilepsy, Parkinson's disease (PD) and rheumatoid arthritis (RA). Subjects were included if they received ≥1 dispensation for a disease-related drug between 1 January 1997 and 31 December 2014.
main outcome measuresProportion of subjects with optimal adherence (≥80%) measured by the medication possession ratio 1 year after the index date (first dispensation of disease-related drug).
results126 478 subjects were included in the primary analysis (MS, n=6271; epilepsy, n=55 739; PD, n=21 304; RA, n=43 164). Subjects with epilepsy (adjusted OR, aOR 0.29; 95% CI 0.19 to 0.45), PD (aOR 0.42; 95% CI 0.29 to 0.63) or RA (aOR 0.26; 95% CI 0.19 to 0.35) were less likely to have optimal 1-year adherence compared with subjects with MS. Within the MS cohort, adherence was higher for DMD than for chronic-use non-MS medications, and no consistent patient-related predictors of adherence were observed across all four non-MS medication classes, including having optimal adherence to DMD.
conclusionsSubjects with MS were significantly more likely to have optimal 1-year adherence than subjects with epilepsy, RA and PD, and optimal adherence appears related to treatment-specific factors rather than patient-related factors. This supports the hypothesis that higher adherence to the MS DMDs could be due to the specialised support programmes; these programmes may serve as a model for use in other chronic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.